(redirected from Biological therapy)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: treatment
References in periodicals archive ?
If patients fulfill the criteria for a biological therapy then, I believe, it is important that treatment is started with minimal delay[4].
The series contains the following journals: Expert Opinion on Biological Therapy, Expert Opinion on Drug Metabolism & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on Pharmacotherapy, Expert Opinion on Therapeutic Patents, and Expert Opinion on Therapeutic Targets.
Any emerging biological therapy with a novel mechanism of action will be positioned after TNF-alpha inhibitors until it accumulates adequate safety data.
The International Society for Biological Therapy of Cancer annual meeting facilitates exchange of the most cutting edge preclinical and clinical data on the use of biological therapies in cancer between basic scientists and clinicians from academic, regulatory and industrial venues.
The first article entitled "Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer" (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.
4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.
Elias is a member of the American Society of Hematology, American Society of Clinical Oncology, International Society of Biological Therapy for Cancer and American Association for Cancer Research.
a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-EpCAM antibody adecatumumab (MT201) against KRAS-mutated human colon cancer cells on November 1, 2008 at the 23rd Annual meeting of the International Society for Biological Therapy of Cancer (iSBTc) , taking place October 31-November 2, 2008 in San Diego, California.
These results will be presented in a poster session at the International Society for Biological Therapy of Cancer meeting in Alexandria, VA on Saturday, November 12, 2005.
From 2012 to 2017, annual market growth will slow due to fewer new product launches, restrictions imposed by third-party payers that will prevent expansion of biological therapy into earlier lines of treatment, biogeneric erosion and smaller increases in the rates of diagnosis and drug treatment.
SYDNEY, Australia & SAN DIEGO -- Avantogen (ASX:ACU) today announced the acceptance of a scientific paper entitled, "Synergistic Effects of Immune Agonists on Efficacy of Vaccines" for the 20th Annual Meeting of the International Society for Biological Therapy of Cancer.

Full browser ?